Hims & Hers Health Inc. (HIMS) shares plummeted 26.2% during Monday's early trading session. The company has abandoned its plan to sell compounded semaglutide tablets, citing regulatory scrutiny from the FDA and potential legal challenges. Concurrently, shares of Novo-Nordisk A/S (NVO), the maker of the branded drug Wegovy, saw an increase in their stock price.